Antibiotic Therapy in Asthma as One of First Step Treatment, a Phase 3 Randomized Clinical Trial

Majid Mirsadraee; Sara Nejati; Shadi Ghafari

doi:10.18502/jmb.v12i3.16609

Antibiotic Therapy in Asthma as One of First Step Treatment, a Phase 3 Randomized Clinical Trial

Majid Mirsadraee

Sara Nejati

Shadi Ghafari

Abstract

Background:   Focus of this study was on subjects suffering from new onset asthma, but actually, they may involve with an infection. Objectives: The target of this study was to determine the frequency of total control of asthma in new onset asthma.
Methods:    this is a phase 3 randomized clinical trial. The participants were 50 new onset asthma, who feel suffering from respiratory infection, however the physician diagnosis was asthma according to wheezy chest, spirometry and clear chest roentgenogram. Age less than 18 years and pregnant women were excluded. The subjects were randomly divided into two groups, doxycycline hyclate and the placebo arms. The drugs were repacked in similar in shape container. Primary endpoint was time to first recurrence. Secondary endpoints were frequency of total control of asthma, dyspnea, cough, asthma control test (ACT) score, FEV1, FEV1/FVC, eosinophil and neutrophil in blood and sputum.
Results:   The difference of clinical findings between two groups before the trial were not significant. Ten percent reported acute attack of asthma during last two months. Treatment with Doxycyline revealed significant improvement of clinical findings, asthma attack and ACT score after two months of treatment, however, complete resolution of clinical findings were significantly higher in Doxycyline group compare to placebo. Clinical findings and FEV1 percent predicted in Doxycyline group T2low asthma group showed significant improvement which were not depicted in T2high group. Eighteen months follow up of the subjects showed complete resolution of asthma symptoms in 12 (48%) on Doxycyline group, which was significantly higher than control group (5 (20%). Time to first exacerbation in doxycycline group was 13.6±5.64 months which was significantly longer than control group (7.49±6.95, P=0.002). Time to first exacerbation in CRP positive was significantly longer (13.64±5.35 months) than CRP negative subjects (9.67±7.76 months, P=0.02).
Conclusion: Doxycycline is an effective antibiotic for preventing recurrence of asthma, in selected new subjects who suspicious for respiratory infection.

1. Lillington G, Faul J. Differential diagnosis of asthma in adults. in: Gershwin, M.E., Albertson, T.E. (eds) Bronchial Asthma. Humana Press, 2001, Totowa, NJ. P. 251.
2. Torres A, Niederman M, Chastre J, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia. Euro Respir J 2017; 50(3) 1700582;
3. Johnson J, Abraham T, Sandhu M, et al. Differential Diagnosis of Asthma. Allergy and Asthma 2019; 23:383-400.
4. Blasi F, Johnston SL. The role of antibiotics in asthma. Int J Antimicrob Agents 2007; 29(5):485-93.
5. Milgrom H, Wood RP, Ingram D. Respiratory conditions that mimic asthma. Immunology and Allergy Clinics of North America 1998; 18(1):113-32.
6. Schwarze J, Gelfand EW. Respiratory viral infections as promoters of allergic sensitization and asthma in animal models. Euro Respir J 2002; 19:341.
7. Gon Y, Hashimoto S. Role of airway epithelial barrier dysfunction in pathogenesis of asthma. Allergol Int 2018; 67(1):12-7.
8. Mthembu N, Ikwegbue P, Brombacher F, et al. Respiratory viral and bacterial factors that influence early childhood asthma. Front allergy 2021; 22.
9. Yano T, Ichikawa Y, Komatu S. Association of Mycoplasma pneumoniae antigen with initial onset of bronchial asthma. Am J Respir Crit Care Med 1994; 149:1348–1353.
10. Nagayama Y, Tsubaki T, Toba T, et al. Role of bacterial infection in the exacerbation of acute or prolonged asthma attack in children. Allergology Int 1999; 48:137–44.
11. Shamim S, Agarwal A, Ghosh BK, et al. Fungal pneumonia in intensive care unit: when to suspect and decision to treatment: a critical review. J Assoc Chest Phys 2015; 3(2):41.
12. Mirzazadeh F, Berenji F, Amini M, et al. Lophomonas blattarum in asthmatic patients and control group. J Res Med Dent Sci 2017; 5(5):1-5.
13. Hilty M, Burke C, Pedro H, et al. Disordered microbial communities in asthmatic airways. PLoS ONE 2010; 5:e8578.
14. Hajam IA, Dar PA, Shahnawaz I, et al. Bacterial flagellin—a potent immunomodulatory agent. Exp Mol Med 2017; 49:e373.
15. Williams LK, Ownby DR, Maliarik MJ, et al. The role of endotoxin and its receptors in allergic disease. Ann Allergy Asthma Immunol 2005; 94:323–32.
16. Swamy M., Jamora C., Havran W., et al. Epithelial decision makers: in search of the epimmunome. Nat Immunol 2010; 11:656–665.
17. Yang X, Li H, Ma Q, et al. Neutrophilic asthma is associated with increased airway bacterial burden and disordered community composition. Biomed Res Int 2018; 9:9230234.
18. Ahmadizar F, Vijverberg SJH, Arets HGM, et al. Early life antibiotic use and the risk of asthma and asthma exacerbations in children. Pediatr Allergy Immunol 2017; 28(5):430-7.
19. Taylor SL, Leong LEX, Choo JM, et al. Inflammatory phenotypes in patients with severe asthma are associated with distinct airway microbiology. J Allergy Clin Immunol 2018; 141(1):94-103.e15.
20. Fabbrizzi A, Amedei A, Lavorini F, et al. The lung microbiome: clinical and therapeutic implications. Intern Emerg Med 2019; 14(8):1241-50.
21. Brusselle GG, VanderStichele C, Jordens P, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax 2013; 68(4):322-9.
22. Sadeghdoust M, Mirsadraee M, Aligolighasemabadi F, et al. Effect of azithromycin on bronchial wall thickness in severe persistent asthma: A double-blind placebo-controlled randomized clinical trial. Respir Med 2021; 185:106494.
23. Pestel M. Doxycycline in the treatment of respiratory tract infections. results of a pan-European multi-centre trial. Chemotherapy 1975; 21 Suppl 1:91-108.
24. Maesen FP, Davies BI, van Noord JA. Doxycycline in respiratory infections: a re-assessment after 17 years. J Antimicrob Chemother 1986; 18(4):531-6.
25. Malka J, Spahn JD. When Cough Wheeze and Shortness of Breath Don't Equal Asthma. J Allergy Clin Immunol Pract 2016; 4(1):179-81.
26. Weinberger M, Abu-Hasan M. Pseudo-asthma: when cough, wheezing, and dyspnea are not asthma. Pediatrics 2007; 120(4):855-64.
27. Sajjan U, Corey M, Humar A et al. Immunolocalisation of Burkholderia cepacia in the lungs of cystic fibrosis patients. J Med Microbiol 2001; 50:535-46.
28. Dong X, Ding M, Zhang J, et al. Involvement and therapeutic implications of airway epithelial barrier dysfunction in type 2 inflammation of asthma. Chin Med J 2022; 135:519-31.
29. van Schilfgaarde M, Eijk P, Regelink A, et al. Haemophilus influenzae localized in epithelial cell layers is shielded from antibiotics and antibody-mediated bactericidal activity. Microb Pathog 1999; 26:249-62.
30. Wang Z, Xin L, Zhang W. Study effect of azithromycin and doxycycline in mucus producing and inflammatory signaling pathways of allergic asthma. Iran J Allergy Asthma Immunol 2022; 21(2):119-27.
31. Patel RS, Parmar M. Doxycycline Hyclate. [Updated 2023 May 22]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. (Available from: https://www.ncbi.nlm.nih.gov/books/NBK555888/)
32. Bonnetblanc JM. Doxycycline [Doxycycline]. Ann Dermatol Venereol. 2002 Jun-Jul;129(6-7):874-82. French.
33. Ghaderi Y, Mirsadraee Y, Berenji F, et al. Frequency of Lophomonas blattarum in asthmatic subjects and effect of anti-lophomonas treatment on asthma, A phase 3 clinical trial. Ubpublished data.
34. Lee KS, Jin SM, Kim SS, Lee YC. Doxycycline reduces airway inflammation and hyperresponsiveness in a murine model of toluene diisocyanate-induced asthma. J Allergy Clin Immunol 2004; 113(5):902-9.
35. Von Hertzen L, Töyrylä M, Gimishanov A, et al. Asthma, atopy and Chlamydia pneumoniae antibodies in adults. Clin Exp Allergy 1999; 29(4):522-8.
36. Bhattacharyya P, Paul R, Bhattacharjee P, et al. Long-term use of doxycycline can improve chronic asthma and possibly remodeling: the result of a pilot observation. J Asthma Allergy 2012; 5:33-7.
37. Feng Y, Li M, Yangzhong X, et al. Pyroptosis in inflammation-related respiratory disease. J Physiol Biochem 2022; 78(4):721-37.
38. Dzhindzhikhashvili MS, Joks R, Smith-Norowitz T, et al. Doxycycline suppresses Chlamydia pneumoniae-mediated increases in ongoing immunoglobulin E and interleukin-4 responses by peripheral blood mononuclear cells of patients with allergic asthma. J Antimicrob Chemother 2013; 68(10):2363-8.
39. Bertuzzi M, Hayes G, Bignell E. Microbial uptake by the respiratory epithelium: outcomes for host and pathogen. FEMS Microbiol Rev 2019; 43(2):145-61.
40. Murphy TF, Brauer AL, Schiffmacher AT, et al. Persistent colonization by Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Resp Crit Care 2004; 170:266-72.

Files	XML pdf (399KB)
Issue	Vol 12 No 3 (2024)
Section	Original Articles
DOI	https://doi.org/10.18502/jmb.v12i3.16609
Keywords
Antibiotic therapy Asthma Bacterial translocation Doxycycline Pseudoasthma.

Rights and permissions
	This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite

Mirsadraee M, Nejati S, Ghafari S. Antibiotic Therapy in Asthma as One of First Step Treatment, a Phase 3 Randomized Clinical Trial. J Med Bacteriol. 2024;12(3):35-43.

Vancouver

Download Citation